Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer


A Phase 2, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy




To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.

Study Status: Withdrawn


Condition Intervention Phase
Breast Cancer Drug: IPI-504 Phase 1/Phase 2

Verified by MedImmune LLC February, 2010

Sponsored by: MedImmune LLC
Information provided by: MedImmune LLC identifier: NCT00627627

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Active Control, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Medical Center
Cleveland, Ohio 44195
United States

David E. Weng, M.D., PhD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site